Health ❯ Chronic Conditions

Obesity

Treatment Options Diabetes Weight Management Type 2 Diabetes Hypertension Inflammation Health Risks Adipositas Weight Loss Medications Comorbidities Weight Loss Weight Loss Drugs Insulin Resistance Heart Disease Medication BMI Management Strategies Medical Outcomes Medication Management Heart Health Related Health Issues Clinical Obesity Weight Loss Supplements Drug Side Effects Management of Obesity Metabolic Factors Nutritional Deficiencies Cardiovascular Health Clinical Guidelines Medication Risks Body Mass Index Stroke BMI Categories Cardiometabolic Health BMI Classification High Cholesterol Weight Regain Cardiovascular Diseases Dietary Impact Impact on Sleep Elderly Care Infectious Diseases Statistics Diabetes Management Dietary Restrictions Multidisciplinary Care Diabetes Type 2 Treatment Plans Management Weight Loss Strategies Health Outcomes Treatment Approaches Metabolic Syndrome Treatment Guidelines Pulmonary Hypertension Surgical Treatments Lifestyle Changes Dietary Management Metabolic Health Joint Disorders

U.S. Spending on GLP‑1 Drugs Rises to $64.9 Billion as Patient Costs Bite

High out‑of‑pocket payments are driving many patients to stop treatment, prompting calls for insurers and lawmakers to curb cost sharing.

Eli Lilly Breaks Ground on $6.5 Billion Houston Campus to Make Oral GLP-1 Pill

Retailers Move to Fill $50 Medicare GLP‑1 Prescriptions

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

UCL Review Finds GLP‑1 Drugs Reduce Binge Eating Symptoms

Medicare Launches 18‑Month GLP‑1 Bridge to Cover Weight‑Loss Drugs

Lawmakers Demand Answers After Single Patient Received Experimental Eli Lilly Obesity Drug

Shaquille O’Neal Says Zepbound Has Eased His Obstructive Sleep Apnea

Lilly’s GLP‑1 Sales and PBM Coverage Fuel Record Quarter as Pipeline Logs Durable Wins

PCOS Is Officially Renamed PMOS After Global Consensus

Study Links Longer, Frequent, Morning Naps to Higher Death Risk in Older Adults

GLP-1 Weight-Loss Draws Harsher Stigma Than Lifestyle Change, Study Finds

New Analyses Link GLP-1 Drugs to Modest Bone and Gout Risks, With Mixed Patterns by Diabetes Status

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

JAMA Forecast: Nearly Half of U.S. Adults Could Have Obesity by 2035

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Oxford Review Finds GLP-1 Weight Loss Largely Lost Within About Two Years After Stopping

Six Midlife Depressive Symptoms Tied to Higher Dementia Risk Decades Later

Florida Supreme Court Lets Frank Walls’ Execution Proceed as Federal Appeal Targets Lethal-Injection Practices

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs